Orbit Market Insights

Executive Summary Amgen Inc. (AMGN) represents a formidable force in the biopharmaceutical industry, balancing a mature, high-performing product portfolio with a strategic focus on innovation and pipeline expansion. Our analysis for Orbit Research suggests that AMGN offers a compelling investment proposition for long-term investors seeking a blend of stability, growth potential, and shareholder returns. Despite facing the inevitable challenges of patent expirations and increasing biosimilar competition for some of its blockbuster drugs, Amgen's robust R&D engine, strategic acquisitions—most notably Horizon Therapeutics—and a strong financial position underpin its resilience and future growth trajectory. The company's consistent dividend payouts and share repurchase programs further enhance its appeal to income-focused investors. We view Amgen as a foundational holding in a diversified healthcare portfolio, positioned to navigate industry headwinds through therapeutic dive...